Literature DB >> 11573856

Acute hepatitis induced by cyproterone acetate.

N Giordano1, P Nardi, C Santacroce, S Geraci, C Gennari.   

Abstract

OBJECTIVE: To report a case of acute hepatitis resulting from the use of cyproterone acetate, an adjuvant treatment for prostate cancer. CASE
SUMMARY: An 87 year-old white man, admitted to surgery for prostate cancer, received cyproterone acetate 300 mg/d orally and developed acute hepatitis, which initially was diagnosed clinically. A liver biopsy showed changes suggestive of acute cholestatic hepatitis. Cyprotorone was stopped immediately, and the patient was subsequently treated with corticosteroids. He then improved rapidly. DISCUSSION: Cyproterone acetate is thought to be well tolerated, but some authors have reported severe hepatic reactions, in particular acute hepatitis, fatal fulminant hepatic failure, and hepatocellular carcinoma. The above-mentioned hepatotoxicity represents an idiosyncratic drug reaction, probably due to the hepatomitogen action of cyproterone, causing an increase of hepatocytes expressing placental glutathione S-transferase, which are considered preneoplastic elements.
CONCLUSION: This case suggests the possibility of hepatotoxicity from cyproterone.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11573856     DOI: 10.1177/106002800103500902

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  3 in total

Review 1.  Hepatotoxicity induced by cyproterone acetate: a report of three cases.

Authors:  Ioanna Savidou; Melanie Deutsch; Aspasia S Soultati; Dimitrios Koudouras; Georgia Kafiri; Spyridon P Dourakis
Journal:  World J Gastroenterol       Date:  2006-12-14       Impact factor: 5.742

2.  Delayed Presentation of Drug-Induced Hepatic Injury.

Authors:  Shohana Ahmed; Nirmal K Onteddu; Ali Jabur; Sai Swarupa R Vulasala; Swapna Kolli
Journal:  Cureus       Date:  2020-08-13

3.  Cyproterone acetate acts as a disruptor of the aryl hydrocarbon receptor.

Authors:  Chih-Shou Chen; Guan-Lun Gao; Dong-Ru Ho; Chih-Yi Lin; Yu-Ting Chou; Shan-Chun Chen; Min-Cong Huang; Wen-Ya Kao; Jyan-Gwo Joseph Su
Journal:  Sci Rep       Date:  2021-03-09       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.